Sitagliptin Triazole Hydrochloride CAS 762240-92-6 Puritas >99.0% (HPLC)
Supple Sitagliptin Phosphate Monohydratorum intermedia:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydratum API CAS 654671-77-9
Acidum trifluorophenylaceticum 2,4,5-
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acidum CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydratum Intermediate CAS 486460-21-3
Nomen chemicum | 3-(Trifluoromethyl) -5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride |
Synonyma | Sitagliptin Triazole Hydrochloride;Sitagliptin medium A |
CAS Number | 762240-92-6 |
CATTUS Number | RF-PI1193 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C6H7F3N4·HCl |
M. Pondus | 228.60 |
Liquescens punctum | 236.0~ 246.0℃ |
Solubilitas | Solutum in Methanol |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Alba ad Off-White Crystalline pulveris |
Lepidium sativum ab HPLC | Retention tempus specimen concordat cum reference vexillum |
Lepidium sativum IR | Obsequitur |
Damnum in Siccatio | <0.50% |
Substantiae cognatae | |
Unam immunditiam | <0.50% |
Totalis immunditias | <1.00% |
Metalla gravis | <20ppm |
Puritas / Analysis Methodus | >99.0% (HPLC) |
Test Standard | Enterprise Standard |
Consuetudinem | Sitagliptin Phosphate Monohydratorum medium (CAS: 654671-77-9) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.
3-(Trifluoromethyl) -5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinum hydrochloridum (CAS: 762240-92-6) intermedium est inter Sitagliptin Phosphatis Monohydratorum (. CAS: 654671-77-9), qui est inhibitor ore-selectivus selectivus DPP4 qui per "optimizationem ordinis β-aminoacidi-deductum DPP4 inhibitores" deprehensus est.DPP4 activitatem sustentato modo subsecuto semel cottidianam administrationem demittit, integras GIP et GLP1 gradus circulationes sequentes in studiis tam acutis quam chronicis conservat ac sanguinem glucosum minuit, sine notabili incremento in hypoglycaemia.Sitagliptin phosphatum (STG) tractare DM specie 2 adhibetur, quia imperium glycemicum auget augendo gradus incretinorum hormonum activorum, GLP-I (peptide-1) et GIP (glucoso-dependens insulinotropico peptidis).STG a FDA in 2006 probatus est.